Viewing nowCombinationDucanazen Tablet 60/2.5 milligrams
Fimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
TerraGen Etex Co., Ltd.

MFDS item code 202300110 · Approved 2023.01.06 · Insurance code 698504700
Treatment of essential hypertension not controlled with fimasartan monotherapy
This medication is used in the treatment of essential hypertension when blood pressure control is insufficient with Pimizartan potassium monotherapy. Essential hypertension is characterized by persistently high blood pressure that can cause various complications. This medication effectively lowers blood pressure, helping to maintain healthy vascular condition. Therefore, it is recommended as a beneficial treatment option for patients with difficult blood pressure control.
Adults The recommended dose is 1 tablet once daily, taken with water regardless of meals. It is recommended to take the tablet at the same time each day, if possible (e.g., in the morning). It is recommended to adjust the dose of fimasartan before administering this medicine; however, if blood pressure is not controlled as described below, switching directly to this medicine may be considered. ㆍ 30/2.5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 30 mg monotherapy. ㆍ 60/2.5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy. ㆍ 60/5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy or this medicine 60/2.5 mg. Patients taking fimasartan and S-amlodipine (amlodipine) concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Elderly patients No initial dose adjustment is necessary for elderly patients aged 70 years or younger. Patients with renal impairment No dose adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance 30 ~ 80 mL/min). However, in patients with severe renal impairment (creatinine clearance < 30 mL/min), treatment should be initiated with fimasartan 30 mg in this medicine. Patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment. However, this medicine should not be administered to patients with moderate to severe hepatic impairment.
The safety and efficacy of this medicine have not been established in pediatric and adolescent patients aged 18 years or younger.
This medication may cause serious harm to the fetus and newborn if taken during pregnancy, especially in the second and third trimesters; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to the active ingredients or similar class of medications, those who are pregnant or breastfeeding, and patients undergoing renal dialysis or with severe liver disease, and those with biliary obstruction should not take this medication. Also, patients with certain kidney issues among diabetes patients, those with specific genetic metabolic disorders, severe aortic stenosis, and those in shock should not use this medication. Caution should be exercised in patients with low blood volume or reduced sodium levels, impaired kidney function, renal artery hypertension, valvular disease, elderly patients, etc., particularly regarding symptoms of hypotension during initial administration. Rare side effects may include dizziness, headache, facial or peripheral edema, urinary disorders, insomnia, flushing, etc.; consult a doctor if symptoms persist or worsen. Regular monitoring of blood pressure, kidney function, and serum potassium levels is essential during medication use, and potential interactions may occur with other antihypertensives, potassium-sparing diuretics, and certain analgesics, so it is crucial to inform healthcare professionals of any concurrent medications. Women of childbearing potential should confirm pregnancy status while taking this medication and discontinue it immediately if pregnant; breastfeeding is not recommended while taking this medication. Safety in children has not been established, and caution is advised in elderly patients. In case of overdose, hypotension, arrhythmias, and, in severe cases, shock may occur; seek medical attention immediately for appropriate treatment. Store this medication in a place where children cannot reach and do not transfer it to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light and should be stored in a container that prevents light exposure. Additionally, it should be stored at room temperature between 1 and 30 degrees Celsius to maintain its effectiveness.
Yellow quadrilateral film-coated tablet with rounded corners
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
TerraGen Etex Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
NBK Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Ajou Pharmaceuticals Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.